Engineered probiotic microbes are emerging as pharmaceutical agents for treating inflammatory conditions. This study engineered *Saccharomyces boulardii* to bind to extracellular matrix (ECM) proteins in the gut using antibody surface display. This resulted in a 24–48 h increase in gut residence time and 100-fold higher colon concentrations in colitis models. Improved pharmacodynamic parameters (colon length, cytokine expression, inflammation scores) were observed, highlighting the potential for targeted microbial therapeutics in inflammatory bowel diseases.
Publisher
Nature Communications
Published On
May 06, 2024
Authors
Mairead K. Heavey, Anthony Hazelton, Yuyan Wang, Mitzy Garner, Aaron C. Anselmo, Janelle C. Arthur, Juliane Nguyen
Tags
probiotic
inflammatory bowel diseases
gut microbiome
pharmaceutical agents
targeted therapy
colon concentration
inflammation
Related Publications
Explore these studies to deepen your understanding of the subject.
